Coeptis Therapeutics Announces First Customer Adoptions of its NexGenAI Marketing Platform

Coeptis Secures Five New Clients With Total Contract Value of $1.7 Million Dollars With More On The Horizon Signaling AI-Driven Marketing Innovations in Biopharma for CoeptisWEXFORD, Pa., Jan. 7, 2025 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, is excited to announce the initial rollout of its recently introduced NexGenAI Affiliates Ne ...